Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study|
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
|Citation:||Internal Medicine Journal, 2014; 44(8):813-817|
|B. O'Carrigan, M. Fournier, I. N. Olver, M. R. Stockler, H. Whitford, G. C. Toner, D. B. Thomson, I. D. Davis, F. Hanning, N. Singhal, C. Underhill, P. Clingan, A. McDonald, A. Boland, P. Grimison and Australian and New Zealand Urogenital and Prostate Cancer Trials Group|
|Abstract:||This is the first prospective study in a contemporary Australian/New Zealand population to determine the prevalence of testosterone deficiency in testicular cancer survivors at 12 months from treatment, and any association with poorer quality of life. Hormone assays from 54 evaluable patients in a prospective cohort study revealed biochemical hypogonadism in 18 patients (33%) and low-normal testosterone in 13 patients (24%). We found no association between testosterone levels and quality of life (all P > 0.05). Hypogonadal patients should be considered for testosterone replacement to prevent long-term morbidity.|
|Keywords:||testicular cancer; hypogonadism; quality of life|
|Rights:||© 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians|
|Appears in Collections:||Aurora harvest 7|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.